Press release

New study to evaluate the diagnostic accuracy of non-contrast flatdetector CT compared to multi slice CT 

Published on July 20, 2022
<p><br></p><ul><li><strong>Multi-center clinical trial SPINNERS initiated by Prof. Marios-Nikos Psychogios and Dr. Adam S. Arthur<br></strong></li><li><strong>If the outcome of the study shows non-inferiority of flatdetector CT, this will support the one-stop-management approach in acute ischemic stroke&nbsp;<br></strong></li></ul><p><br></p><p>SPINNERS stands for "ProSPective evaluation of the dIagnostic accuracy of siNe spiN non-contrast flat-dEtectoR CT (FDCT) for the detection of intracranial hemorrhage in stroke patients". The just registered study is an investigator-initiated clinical trial performed at multiple sites in Switzerland, Austria, and the US. If the outcome of the study shows non-inferiority of flatdetector CT, this will support the one-stop-management (or angio only) approach which may improve diagnosis, door to needle time and, subsequently, the outcome for acute ischemic stroke patients. In this workflow, both imaging for the diagnosis of the LVO and the subsequent thrombectomy are carried out with the help of FDCT right inside the angiography room<sup>1</sup>.</p><p>Stroke and cerebrovascular disease are among the leading causes of death and disability worldwide. Stroke can be caused by either circulatory disorders (ischemic cerebral infarction) or bleeding into the brain (hemorrhagic stroke). To clinically differentiate these disease states, which require different therapies, a non-contrast computed tomography scan of the head is currently state-of-the-art.</p><p>According to the American Heart Association, 795,000 strokes are occurring in the US each year. Around 87 percent are caused by ischemic cerebral infarctions<sup>2</sup>. Following the publication of five large studies<sup>3,4</sup>, mechanical thrombectomy became the gold standard for the treatment of acute ischemic stroke caused by large-vessel occlusion (LVO).</p><p>This minimally invasive procedure requires a neurointerventionalist and should be performed as early as possible after the onset of stroke symptoms (“time is brain” concept). However, lifesaving thrombectomy may often be delayed.<sup>5,6</sup> One way to significantly shorten the time to treatment is to implement a "one-stop-management" approach for severe strokes, e.g., patients presenting with an NIHSS<sup>7</sup> value larger than 9.</p><p>One of the biggest hurdles to a large-scale implementation of the one-stop-management approach so far has been the lack of clinical evidence to prove a reliable distinction between ischemic and hemorrhagic stroke by means of FDCT. Artifacts and decreased image quality near the base of the skull limited its use to that of a triage tool in previous generations of angiography systems.</p><p>With the SPINNERS study, the initiators plan to investigate whether FDCT imaging with syngo DynaCT Sine Spin (a novel imaging protocol available on the Artis icono angiography system) has a non-inferior diagnostic accuracy to MDCT (Multi Detector Computed Tomography) in detecting intracranial bleedings.</p><p>Initiators and principal investigators of the SPINNERS study are Prof. Marios-Nikos Psychogios, Head of Diagnostic and Interventional Neuroradiology, University Hospital Basel, Switzerland and Dr. Adam S. Arthur, Chair of Neurosurgery at the University of Tennessee Health Sciences Center and Semmes-Murphey Clinic, Memphis, TN, US. The multi-center study is planned to be conducted at approximately 12 clinical sites in Switzerland, Austria, and the US, and is designed to include 252 patients. The SPINNERS study is funded by Siemens Healthineers.</p> <p>The SPINNERS study is registered under <a href="https://www.clinicaltrials.gov/ct2/show/NCT05458908?term=05458908&draw=2&rank=1" target="_blank">https://www.clinicaltrials.gov/ct2/show/NCT05458908?term=05458908&amp;draw=2&amp;rank=1</a></p>
1
2
3
4
5
6
7

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.